Sagimet Biosciences (STU:0O2) Accounts Receivable: €0.00 Mil (As of Mar. 2026)

What is Sagimet Biosciences Accounts Receivable?

Sagimet Biosciences STU:0O2 +1.66% 10 Accounts Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Sagimet Biosciences's accounts receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Sagimet Biosciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €2.63.

Sagimet Biosciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Sagimet Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Sagimet Biosciences's accounts receivable are only considered to be worth 75% of book value:

Sagimet Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(90.426	+	0.75 * 0	+	0.5 * 0	-	4.582
-	0	-	0)	/	32.585
=	2.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Sagimet Biosciences Accounts Receivable Related Terms

Sagimet Biosciences Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Accounts Receivable can be seen below:

Sagimet Biosciences Accounts Receivable Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Accounts Receivable

Get a 7-Day Free Trial

0.00

Sagimet Biosciences Quarterly Data
	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Accounts Receivable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

10GF Score

Sagimet Biosciences Inc STU:0O2

Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sagimet Biosciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →

What does a Accounts Receivable of €0.00 Mil mean?

Sagimet Biosciences (STU:0O2) has a Accounts Receivable of €0.00 Mil as of Mar. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Sagimet Biosciences and its competitors.

Is Sagimet Biosciences' Accounts Receivable too high?

Sagimet Biosciences' current Accounts Receivable is €0.00 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Sagimet Biosciences' Accounts Receivable compare to EDIT and AUTL?

Sagimet Biosciences' Accounts Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Accounts Receivable for a Biotechnology company?

A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Accounts Receivable mean?

A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Accounts Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sagimet Biosciences stock overvalued right now?

Sagimet Biosciences (STU:0O2) has a current Accounts Receivable of €0.00 Mil. The current Accounts Receivable is €0.00 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Accounts Receivable calculated?

Accounts Receivable is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Accounts Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies EDIT AUTL FBRX BNTC INDP IPSC PBYI ENTA ARTV OVID VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SGMT:USA

Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website https://www.sagimet.com

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

10GF Score

Get the complete analysis for STU:0O2

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14

Price

View STU:0O2 Analysis

See Accounts Receivable data for all stocks →